lyophil_margin

TL3 Regular · Klaipėda, LT

Laboratory background. Comfortable with chromatography, cautious about extrapolating from a single certificate.

Joined 26 September 2024 · last posted 2d · groups: analytical-chemists

138 posts, newest first. Showing up to 150.

Deletion sequences: expected mass shifts by residue — the long version Replied, post #24 · Analytics › Impurities & related substances · 26 Jul 2026 · 6 likes No disagreement from me. Posting only so the question does not look ignored.
CJC-1295 with and without DAC: what the modification does Replied, post #121 · Compounds › Secretagogues & GH axis · 24 Jul 2026 · 1 like CJC-1295 looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
Coming back to: Preparing for an appointment: one page, three questions Replied, post #42 · Clinical › Prescriber conversations · 24 Jul 2026 · 12 likes Narrowing post #41, because the general version has more than one answer. Take the actual numbers and the actual dates. A printed table beats a description and takes…
Request: a per-category review queue Replied, post #125 · Meta › Feature requests · 23 Jul 2026 · 4 likes Duplicate requests: if several people request the same feature, the requests often get merged. Check whether your feature has already been suggested before posting.…
Lean mass preservation: what the evidence supports — does this still hold? Replied, post #120 · Outcomes › Body composition · 23 Jul 2026 · 0 likes That is clearer than the version I had in my head. Thank you.
Revisiting: Protein density versus volume when you cannot eat much Replied, post #90 · Nutrition & Training › Protein & intake · 21 Jul 2026 · 13 likes The arithmetic in post #87 is right; the assumption feeding it is the part to check. Protein sources: animal sources (meat, fish, eggs, dairy) are denser and easier to…
Which categories are strict and which are relaxed, honestly Replied, post #22 · Start Here › Welcome · 17 Jul 2026 · 19 likes On the reading order question specifically: start with the how-to-ask materials in this category, then read the one to three subcategories where your main questions…
Seven-day rolling means and why weekly readings mislead Replied, post #44 · Outcomes › Progress reports · 16 Jul 2026 · 11 likes Measurement noise: day-to-day body mass varies by more than a kilogram on hydration, glycogen, and gut contents alone. A weekly reading is a single noisy sample of a…
How shortages have affected compounding permissions Replied, post #44 · Access › Shortages · 16 Jul 2026 · 15 likes Reports that a pharmacy has stock are the least durable information on the site and are still worth posting with a date.
Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #31 · Compounds › Semaglutide · 15 Jul 2026 · 18 likes On formulation: the licensed product is buffered and includes a preservative in the multi-dose presentation. A reconstituted research preparation matches neither, and…
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #29 · Analytics › HPLC & UHPLC · 11 Jul 2026 · 20 likes Trifluoroacetic acid at 0.1 per cent is the near-universal ion-pairing additive for this work, and it also raises the baseline at 214 nanometres. That is why the same…
Follow-up: How compounding permissions changed when supply normalised Replied, post #10 · Sourcing › Regulatory · 11 Jul 2026 · 2 likes Building on post #9 rather than restating it. If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the…
MS/MS sequence confirmation: what it costs and when it is worth it Replied, post #5 · Analytics › Mass spectrometry · 8 Jul 2026 · 8 likes Combining a chromatographic result with a mass result is genuinely orthogonal confirmation. Either alone leaves a specific class of problem invisible, and the two…
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #89 · Evidence › Journal club · 8 Jul 2026 · 21 likes SURMOUNT-OSA is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
Trust level 3 requirements: a clarification — does this still hold? Replied, post #77 · Meta › Announcements · 5 Jul 2026 · 33 likes The rare case here is the one that costs somebody a week, though, and the common case costs everyone ten seconds. I think the trade is clearly correct. I would rather…
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #33 · Compounds › Secretagogues & GH axis · 29 Jun 2026 · 24 likes A methods point on GHRH analogues versus ghrelin mimetics rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the…
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #24 · Practice › Dosing & titration · 29 Jun 2026 · 11 likes Research-use-only material is not a licensed product and no labelling covers it. Everything in this subcategory about published schedules describes what was done in…
Primary endpoint hierarchies and why order matters — one year on Replied, post #29 · Evidence › Trials · 29 Jun 2026 · 2 likes Surrogate endpoints: an endpoint that is not the outcome that matters but is measured as a stand-in. HbA1c is a surrogate for long-term glucose control and the…
How shortages have affected compounding permissions Replied, post #2 · Access › Shortages · 27 Jun 2026 · 5 likes Building on the opening post rather than restating it. Careful with the language on shortages. "Not detected" and "not present" are different findings and the first is…
Secretagogues and glucose tolerance: the mechanistic concern Replied, post #45 · Compounds › Secretagogues & GH axis · 22 Jun 2026 · 0 likes Picking up post #42: that is the part I would want checked first. Research-use-only secretagogues are not approved for human use. That statement is doing real work in…
Why we ask for units every single time, with three examples of what goes wrong Replied, post #60 · Start Here › How to Ask · 21 Jun 2026 · 1 like Second this, and I would have said it less carefully.
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #14 · Analytics › Impurities & related substances · 21 Jun 2026 · 0 likes I had written a reply contradicting post #11 and deleted it. Here is what survived. Aggregates: multiples of the monomer mass. May not elute at all under a standard…
Trust level 3 requirements: a clarification — does this still hold? Replied, post #68 · Meta › Announcements · 21 Jun 2026 · 27 likes The moderation log will carry the announcement entry, so the date is recoverable. It will not be visible on the topic itself, which is probably the right level of…
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #46 · Evidence › Journal club · 20 Jun 2026 · 0 likes On STEP 1: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here…
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #113 · Practice › Reconstitution · 17 Jun 2026 · 5 likes Fair, and the limits you put on it are the part I will remember.
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #80 · Data & Tools › Datasets · 14 Jun 2026 · 7 likes Post #79 answers the question as asked. The question underneath it is different. Worth separating community side-effect dataset as a question about the compound from…
Carryover and the ghost peak from last week's standard — what changed since Replied, post #29 · Analytics › HPLC & UHPLC · 13 Jun 2026 · 0 likes I disagree with the framing of Carryover above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.…
What to include when your question involves a chromatogram — one year on Replied, post #32 · Start Here › How to Ask · 10 Jun 2026 · 1 like Taking post #29 at face value and following it one step further. A photograph of a vial is rarely useful and a photograph of a document usually is. Redact the…
Second pass at: Sleep apnoea improving and the equipment implications Replied, post #52 · Wellbeing › Sleep · 6 Jun 2026 · 12 likes Gastrointestinal effects overnight: nausea or reflux or constipation at night can disrupt sleep. Dosing timing (morning versus evening) might help if nighttime GI…
Lean mass preservation: what the evidence supports — does this still hold? Replied, post #88 · Outcomes › Body composition · 3 Jun 2026 · 7 likes Everything in post #84 holds. The case it does not cover is the one I have. Answering the Lean mass preservation question as asked, then the question I think is meant.…
Official shortage notices and what they authorise Replied, post #76 · Access › Shortages · 29 May 2026 · 2 likes Building on post #75 rather than restating it. Stockpiling in response to a shortage worsens it, which is true and is a poor argument to make to somebody who has run…
Follow-up: Sleep quality changes during weight loss Replied, post #28 · Wellbeing › Sleep · 23 May 2026 · 1 like I read post #26 twice before replying, because I had assumed the opposite. Eating patterns shift substantially and late intake affects sleep independently of anything…
Coming back to: Specificity, linearity, accuracy, precision, range, robustness — with… Replied, post #29 · Analytics › Method validation · 22 May 2026 · 8 likes Confirming post #28 from a second method, which matters more than confirming it from a second person. I have no financial interest in anything named in this thread and…
Bariatric surgery history: altered anatomy, altered expectations Replied, post #19 · Clinical › Special populations · 22 May 2026 · 1 like I changed my mind about bariatric surgery history after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is…
Packaging that arrived damaged: documenting it properly Replied, post #12 · Sourcing › Logistics · 20 May 2026 · 4 likes Documentation after arrival: photograph the parcel and its contents on arrival. If something later turns out wrong (damage, loss, wrong item) you have evidence of the…
What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still… Replied, post #24 · Compounds › Retatrutide · 17 May 2026 · 11 likes What would change my mind on TRIUMPH is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than…
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #49 · Practice › Reconstitution · 12 May 2026 · 3 likes Post #47 answers the question as asked. The question underneath it is different. Arithmetic step by step: a 5 mg vial with 2 mL of diluent gives (5 mg) / (2 mL) = 2.5…
EU-wide position versus national implementation — what changed since Replied, post #26 · Regional › European Union · 9 May 2026 · 3 likes Agreed on all of that, and I have nothing to add to it.
GLP-1 receptor distribution: central and peripheral Replied, post #45 · Pharmacology › Receptor biology · 7 May 2026 · 0 likes Long-term receptor changes: very little is known about what happens to receptor expression, signalling, and downstream effects over years of exposure to these…
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just… Replied, post #14 · Compounds › Tirzepatide · 1 May 2026 · 0 likes Post #12 put the caveat in the right place and I want to underline it. On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently…
Follow-up: Reconciling a label claim with a content assay Replied, post #15 · Analytics › COA interpretation · 16 Apr 2026 · 26 likes Water content by Karl Fischer is worth having on a lyophilised product because residual water is both a mass contributor and a stability factor. Reading it again, the…
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #12 · Compounds › Repair & healing peptides · 15 Apr 2026 · 31 likes Thank you for taking the time. That was more work than a reply usually is.
Five questions in one post gets you one answer — how to split them Replied, post #48 · Start Here › How to Ask · 6 Apr 2026 · 22 likes Five questions is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
Follow-up: State-level differences that actually matter Replied, post #8 · Regional › North America · 4 Apr 2026 · 27 likes The arithmetic in post #7 is right; the assumption feeding it is the part to check. Second-hand on State-level differences, so weight it accordingly — someone whose…
Amylin receptor signalling and satiety — what changed since Replied, post #54 · Pharmacology › Receptor biology · 1 Apr 2026 · 2 likes Two things can be true about Amylin receptor signalling and satiety at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the…
[2026 update] Does a peptide degrade silently, with no visual change? Replied, post #40 · Practice › Storage & stability · 29 Mar 2026 · 8 likes Taking peptide seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two…
Ultrasound and skinfolds: operator dependence in practice — what changed since Replied, post #29 · Outcomes › Body composition · 28 Mar 2026 · 12 likes Offering a way to settle Ultrasound and skinfolds rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is…
An ABAB design with a data table and honest limitations — a second dataset Replied, post #80 · Research Methods › N-of-1 designs · 19 Mar 2026 · 23 likes Washout periods: after stopping a medication, how long does it take for the effect to wash out? For compounds with a week-long half-life, roughly a month is needed to…
Revisiting: Absolute versus relative contraindications Replied, post #44 · Safety › Contraindications · 15 Mar 2026 · 25 likes Post #41 answers the question as asked. The question underneath it is different. Trying to state the Absolute versus relative contraindications position in a way that…
Introducing myself: pharmacist, sceptic, reluctant participant — one year on Replied, post #63 · Lounge › Introductions · 14 Mar 2026 · 10 likes Glad to see another member from outside the usual regions. The access and regional categories are thin for anywhere that is not the UK, EU or North America, and a dated…
A payment that went through twice: how it was resolved Replied, post #19 · Sourcing › Payments · 1 Mar 2026 · 5 likes Adding the measurement that post #17 says would settle it. The practical questions in this subcategory are about recourse, records and timing, and none of them are…
Journal club: semaglutide in MASH, and surrogate endpoints Replied, post #9 · Evidence › Journal club · 26 Feb 2026 · 1 like Reading back through the semaglutide in MASH threads from last year, the same three questions come up every time and only one of them has ever been answered properly.…
The most useful thing you learned here that was not the answer you came for Replied, post #23 · Lounge › Off topic · 25 Feb 2026 · 14 likes Saving this. It is the version I will quote when the question comes round again.
Guidelines revision: what changed and why — one year on Replied, post #72 · Meta › Announcements · 18 Feb 2026 · 0 likes Post #69 is the version of this I will quote in future. One addition. My position on Guidelines revision is current rather than settled. I have revised it once already…
Ultrasound and skinfolds: operator dependence in practice — what changed since Replied, post #14 · Outcomes › Body composition · 8 Feb 2026 · 21 likes Bone mineral density changes with substantial weight loss are measurable and slow, and are one of the better reasons to have a baseline scan.
Injection discomfort: needle gauge, volume, temperature, technique Replied, post #23 · Practice › Administration · 6 Feb 2026 · 0 likes Answering the question post #19 raises rather than the one it answers. Where I have landed on injection discomfort, having got it wrong once in public: the direction is…
Reused chromatograms across lots: how to spot it — what changed since Replied, post #12 · Analytics › COA interpretation · 19 Jan 2026 · 0 likes The distinction between release testing and characterisation is one industrial documents make and retail ones usually do not. It is the difference between "we tested…
Half-life, steady state, and accumulation worked through — a second dataset Replied, post #53 · Pharmacology › Pharmacokinetics · 5 Jan 2026 · 1 like Confirming post #52 from a second method, which matters more than confirming it from a second person. Accumulation at steady state: with a week-long half-life,…
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #53 · Access › Pricing · 4 Jan 2026 · 1 like Confirming post #50 from a second method, which matters more than confirming it from a second person. Trying to state the Price changes position in a way that someone…
Promotion criteria, and the one that stops most nominations — the long version Replied, post #125 · Documentation › Doc review · 3 Jan 2026 · 16 likes Worth separating two things that post #121 runs together. Point three stops most nominations. A document without a maintainer becomes wrong quietly, and that is the…
Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #78 · Compounds › Semaglutide · 26 Dec 2025 · 0 likes Quietly grateful for the plain phrasing. Not every thread gets that.
Selection into a registry and what it does to the estimate Replied, post #2 · Evidence › Study critique · 22 Dec 2025 · 18 likes Confirming the opening post from a second method, which matters more than confirming it from a second person. Choosing the worst interpretation: "The confidence…
Revisiting: Journal club: SURMOUNT-1, read without the press release Replied, post #4 · Evidence › Journal club · 22 Dec 2025 · 0 likes I had written a reply contradicting the opening post and deleted it. Here is what survived. Sessions on negative or null results are consistently the most instructive…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long… Replied, post #65 · Compounds › Tirzepatide · 9 Dec 2025 · 7 likes Narrowing post #64, because the general version has more than one answer. I would keep Tirzepatide in type 2 diabetes and the decision it usually gets used for separate…
Documentation that appears only after payment Replied, post #98 · Sourcing › Red flags · 6 Dec 2025 · 0 likes Where I part company with post #96, and it is a narrow parting. The guidelines draw that line for a practical reason as much as a fair one: reports accumulate into…
Reading SURMOUNT-1 without the press release — one year on Replied, post #26 · Compounds › Tirzepatide · 1 Dec 2025 · 29 likes The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against…
Second pass at: The topic list is dense — is that deliberate? Replied, post #10 · Meta › Site feedback · 29 Nov 2025 · 7 likes What I can speak to on topic list is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
Revisiting: Aggregates and why a purity assay may miss them entirely Replied, post #13 · Analytics › Impurities & related substances · 15 Nov 2025 · 0 likes Nothing to add, except that this is the answer I would give if asked.
[2026 update] What steady state means for the decision to escalate Replied, post #58 · Practice › Dosing & titration · 11 Nov 2025 · 16 likes Speaking only to steady state as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the…
Warfarin and altered intake: the monitoring argument — the long version Replied, post #47 · Practice › Interactions · 10 Nov 2025 · 15 likes Picking up post #45: that is the part I would want checked first. Anything that also slows gut motility compounds the same mechanism. That is a plausibility argument…
Coming back to: Why most self-reports here are not experiments, and that is fine Replied, post #15 · Research Methods › N-of-1 designs · 29 Oct 2025 · 1 like It does not tell you about anybody else, which is why aggregating these accounts does not produce evidence of the kind people want it to.
New subcategory: rationale and scope Replied, post #40 · Meta › Announcements · 16 Oct 2025 · 23 likes One question about the transition rather than the policy: what happens to topics that are in flight when it takes effect? The announcement is clear about posts and…
Documentation that materially improves an appeal's chances Replied, post #29 · Access › Insurance & coverage · 15 Oct 2025 · 3 likes That matches what I have seen, for whatever a single anecdote is worth.
Journal club: how we handle discontinuation in obesity trials — what changed since Replied, post #10 · Evidence › Journal club · 10 Oct 2025 · 1 like The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to.
Sleep quality changes during weight loss — what changed since Replied, post #18 · Wellbeing › Sleep · 6 Oct 2025 · 24 likes Worth separating two things that post #16 runs together. Sleep hygiene: basics (cool dark room, consistent sleep time, no screens before bed) matter more during energy…
Which panel is worth repeating and which is worth ignoring Replied, post #121 · Clinical › Bloodwork · 26 Sep 2025 · 4 likes What I would tell a new member reading about panel for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
Payment method and the leverage it gives you, ranked Replied, post #60 · Sourcing › Payments · 23 Sep 2025 · 6 likes Escrow services: some third-party services hold payment until the buyer confirms receipt. They add cost but reduce risk if the supplier is unknown.
Insurance and replacement policies, compared — the long version Replied, post #15 · Sourcing › Logistics · 13 Sep 2025 · 4 likes Anyone deciding whether a delay is a problem should ask what would change if they waited another week. Usually the answer is nothing. Old habit: I write down the…
Aggregated purity results across four services, with caveats — a second dataset Replied, post #88 · Data & Tools › Datasets · 9 Sep 2025 · 11 likes Adding the measurement that post #85 says would settle it. My position on Aggregated purity results across four is current rather than settled. I have revised it once…
What this community means by "a source", in practical terms Replied, post #100 · Start Here › Welcome · 5 Sep 2025 · 10 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
Aggregated purity results across four services, with caveats Replied, post #3 · Data & Tools › Datasets · 3 Sep 2025 · 2 likes A codebook describing each field takes twenty minutes and is what makes the file usable by anyone but you. Most shared datasets here do not have one. The part I am sure…
The nausea timeline across the first four weeks, with a tabulated log — what changed since Replied, post #5 · Practice › Side effects · 22 Aug 2025 · 4 likes Taking post #2 at face value and following it one step further. The thing about nausea timeline that took me longest to accept is that a plausible mechanism is not…
Coming back to: What published stability data actually covers, and what it does not Replied, post #118 · Practice › Storage & stability · 20 Aug 2025 · 0 likes Visible particulate is a strong signal in the other direction: it is a reason to stop and ask rather than to filter and proceed. The mechanism is plausible, which is…
Gauge and length selection for subcutaneous injection Replied, post #20 · Devices › Syringes & needles · 13 Aug 2025 · 6 likes Sharps containers are a legal requirement for disposal in several jurisdictions and a sensible precaution everywhere. A rigid sealed container is the minimum.
A request that was declined, and the reasoning — a second dataset Replied, post #76 · Documentation › Wiki requests · 13 Aug 2025 · 25 likes Link the topics that prompted the request. The discussion is the evidence that the question recurs. I would put a moderate confidence on that and no more.
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Replied, post #33 · Sourcing › Regulatory · 24 Jun 2025 · 3 likes Post #29 describes the usual case. This is about the unusual one. If you can confirm or contradict a position for your own region, please date the answer. An undated…
Sodium, potassium and magnesium when intake drops Replied, post #21 · Nutrition & Training › Hydration & electrolytes · 18 Jun 2025 · 3 likes Adding salt to food is the intervention most consistently reported as helping and is also the one least likely to cause harm. That distinction has done more work for me…
Second pass at: Trial registration and comparing the protocol with the paper Replied, post #28 · Evidence › Trials · 12 Jun 2025 · 10 likes Noted, and I have changed what I was going to do on the strength of it.
[2026 update] An appeal that failed, and what I would do differently Replied, post #41 · Access › Insurance & coverage · 9 Jun 2025 · 30 likes Narrowing post #40, because the general version has more than one answer. Keep every document with dates in one place. An appeal months later is assembled from whatever…
Obstructive sleep apnoea and a hard endpoint in this class Replied, post #104 · Clinical › Comorbidities · 4 Jun 2025 · 0 likes Nothing here is medical advice and clinicians posting in this subcategory say so on their own account rather than because a rule requires it.
What SELECT changed about how semaglutide is discussed, and what it did not Replied, post #125 · Compounds › Semaglutide · 19 May 2025 · 2 likes The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice.…
Ipamorelin selectivity claims and where they came from Replied, post #34 · Compounds › Secretagogues & GH axis · 3 May 2025 · 33 likes Helpful, and short, which on this subject is harder than long.
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Replied, post #15 · Evidence › Journal club · 3 May 2025 · 25 likes The useful distinction on STEP 4 is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Replied, post #24 · Evidence › Journal club · 30 Apr 2025 · 12 likes Post #20 put the caveat in the right place and I want to underline it. I would put moderate confidence on the mainstream reading of SURMOUNT-4 and continuation versus…
Journal club: indirect comparison between two programmes, defended and attacked — one… Replied, post #5 · Evidence › Journal club · 29 Apr 2025 · 4 likes Post #4 is the version of this I will quote in future. One addition. For anyone finding this later: the short answer on indirect comparison is that it depends on one…
UK access routes, dated and sourced — a second dataset Replied, post #68 · Regional › UK & Ireland · 24 Apr 2025 · 1 like Cost comparisons should state whether they include the consultation, the device, the needles and the follow-up, because those differ between routes.
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #127 · Evidence › Journal club · 23 Apr 2025 · 30 likes The question underneath STEP 1 is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it. Write down what you would expect to…
Counter-ion content and its effect on measured mass Replied, post #22 · Analytics › Mass spectrometry · 21 Apr 2025 · 4 likes Monoisotopic and average mass are different numbers and both appear on documents. At this molecular weight the difference is a few daltons, which is more than the…
The C-cell question: rodent findings and their human context Replied, post #9 · Compounds › Semaglutide · 19 Apr 2025 · 1 like Cardiovascular data in people without diabetes is the specific contribution of SELECT, and it is worth being precise that the enrolled population had established…
A well-designed study with a badly written abstract Replied, post #24 · Evidence › Study critique · 14 Apr 2025 · 5 likes Generalisability and validity are separate axes. A trial can be internally impeccable and still tell you nothing about the person asking. Happy to be corrected if…
Follow-up: Open-label extensions: what survives and what does not Replied, post #25 · Evidence › Trials · 3 Apr 2025 · 16 likes I read post #23 twice before replying, because I had assumed the opposite. Open-label extensions has been discussed here with more heat than it deserves, mostly because…
Second pass at: Manufacturer assistance programmes and their eligibility rules Replied, post #18 · Access › Pricing · 27 Mar 2025 · 0 likes I had written a reply contradicting post #14 and deleted it. Here is what survived. The useful distinction on Manufacturer assistance programmes is between what was…
Research-use-only labelling: what it means and what it does not — the long version Replied, post #107 · Sourcing › Regulatory · 17 Mar 2025 · 0 likes Worth separating two things that post #105 runs together. Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if…
Reading an MS report that only gives you a single number Replied, post #26 · Analytics › Mass spectrometry · 10 Mar 2025 · 15 likes I had written a reply contradicting post #22 and deleted it. Here is what survived. Positional isomers and epimers are mass-identical. Any argument that a mass result…
Pharmaceutical compounding rules, summarised from primary sources Replied, post #48 · Sourcing › Regulatory · 1 Mar 2025 · 25 likes Two people in this thread mean different things by pharmaceutical compounding rules and are disagreeing about the definition while believing they are disagreeing about…
Pharmaceutical compounding rules, summarised from primary sources Replied, post #17 · Sourcing › Regulatory · 27 Feb 2025 · 5 likes Post #16 is right about the mechanism and I think understates the practical bit. Post-authorisation safety commitments are public and are one of the more useful sources…
Follow-up: Tesamorelin has an approved indication — what that changes about the evidence Replied, post #15 · Compounds › Secretagogues & GH axis · 24 Feb 2025 · 0 likes Coming back to post #13, because the follow-up matters more than the original answer. Storage: these are lyophilised short peptides and are generally reasonably stable…
Biased agonism: a real phenomenon, an over-used explanation — what changed since Replied, post #57 · Pharmacology › Receptor biology · 20 Feb 2025 · 2 likes Cross-reactivity at related receptors within the secretin family is real and is one reason selectivity claims should be read against the panel that was tested rather…
Biased agonism: a real phenomenon, an over-used explanation — what changed since Replied, post #48 · Pharmacology › Receptor biology · 11 Feb 2025 · 0 likes Receptor occupancy required for a clinical effect is not the same as full occupancy, and dose-response curves flattening at the top is what you would expect from that.…
Consistent declarations and why they matter more than clever ones Replied, post #4 · Sourcing › Logistics · 6 Feb 2025 · 0 likes Picking up post #3: that is the part I would want checked first. My understanding of consistent declarations is a few years old and may have been superseded. If it has…
SURPASS-2 and the comparator dose question that will not go away Replied, post #105 · Compounds › Tirzepatide · 15 Jan 2025 · 10 likes Reading rather than contributing, but this is the most useful thread I have found on it.
Recovery when intake is low: what to cut first Replied, post #54 · Nutrition & Training › Resistance training · 13 Jan 2025 · 30 likes Post #52 and I disagree about the size of the effect, not about the direction. Reduced appetite makes fuelling a session harder, and that is a practical problem with…
Scheduled maintenance and what will be unavailable Replied, post #12 · Meta › Announcements · 10 Jan 2025 · 0 likes Taking scheduled maintenance seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and…
Recovery when intake is low: what to cut first Replied, post #18 · Nutrition & Training › Resistance training · 10 Jan 2025 · 0 likes Reduced appetite makes fuelling a session harder, and that is a practical problem with practical solutions rather than a reason to stop. One more caveat and then I will…
A promotion I argued against, and why I lost Replied, post #48 · Documentation › Doc review · 2 Jan 2025 · 21 likes Worth separating two things that post #46 runs together. Check the links. Promotion frequently breaks a cross-reference because the source topic now points at the…
Coming back to: Grapefruit: why this class is not the class that cares Replied, post #43 · Practice › Interactions · 31 Dec 2024 · 23 likes This follows post #40 rather than contradicting it. Practical experience of Grapefruit, offered as one case with the conditions stated, not as a general finding.…
Body image changing more slowly than the body Replied, post #54 · Wellbeing › Mental health · 17 Dec 2024 · 6 likes Posting my body image numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a particular…
[2026 update] Step therapy requirements and how to satisfy them Replied, post #62 · Access › Insurance & coverage · 9 Dec 2024 · 24 likes Nothing here is legal or medical advice, and appeal processes differ enough by jurisdiction and payer that specifics do not transfer.
[2026 update] Step therapy requirements and how to satisfy them Replied, post #53 · Access › Insurance & coverage · 3 Dec 2024 · 14 likes The failure mode on Step therapy requirements is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple…
Revisiting: Bug report: the reconstitution calculator and a rounding edge case Replied, post #7 · Data & Tools › Calculators · 30 Nov 2024 · 29 likes Following, with nothing to contribute beyond having asked the same thing elsewhere.
Coming back to: When to suspect the method rather than the sample Replied, post #7 · marked as the solution · Analytics › Method validation · 28 Nov 2024 · 15 likes The limit of quantitation determines what the impurity table can honestly contain. Peaks below it can be reported as detected and cannot be reported as a number. That…
Injection-site reactions: describing them precisely enough to be useful Replied, post #30 · Practice › Side effects · 27 Nov 2024 · 7 likes The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of…
Tracking semaglutide's approved indications across jurisdictions, dated — does this… Replied, post #32 · Compounds › Semaglutide · 18 Nov 2024 · 1 like On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study…
Follow-up: Escalating every six weeks instead of four: what I observed over eight months Replied, post #3 · Practice › Dosing & titration · 17 Nov 2024 · 0 likes Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a…
EMA product information as a primary source — does this still hold? Replied, post #54 · Regional › European Union · 16 Nov 2024 · 0 likes EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member…
Glucagon receptor agonism in a weight-loss compound Replied, post #2 · Pharmacology › Receptor biology · 3 Nov 2024 · 0 likes I had written a reply contradicting the opening post and deleted it. Here is what survived. GIP receptor signalling: the glucose-dependent insulinotropic peptide…
Micronutrient status when intake falls substantially — a second dataset Replied, post #4 · Clinical › Bloodwork · 30 Oct 2024 · 2 likes Reference intervals are constructed to contain the central ninety-five per cent of a reference population, so one healthy person in twenty falls outside one by…
Promotion criteria, and the one that stops most nominations Replied, post #97 · Documentation › Doc review · 27 Oct 2024 · 23 likes Check the links. Promotion frequently breaks a cross-reference because the source topic now points at the document rather than the reverse. Someone should write this up…
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Replied, post #59 · Compounds › Other compounds · 19 Oct 2024 · 0 likes Post #57 and I disagree about the size of the effect, not about the direction. Two sentences on Melanocortin agonists and then I will stop, because the rest is…
Why a preprint's supplementary material is often the best part Replied, post #27 · Evidence › Preprints · 17 Sep 2024 · 25 likes Reading back through, this was answered upthread and I missed it. My fault.
Splitting a vial for two laboratories: how to do it without ruining both — what changed… Replied, post #60 · Sourcing › Independent verification · 15 Sep 2024 · 9 likes Narrowing post #57, because the general version has more than one answer. Cross-checking one lot with two services independently is the cleanest test available and is…
Chronic kidney disease and the FLOW result Replied, post #29 · Clinical › Comorbidities · 20 Aug 2024 · 16 likes Multiple comorbidities: a person with diabetes, kidney disease, and cardiovascular disease is outside the studied populations in most trials. Extrapolating to that…
Correlation in a self-tracked dataset: what it can support Replied, post #3 · Research Methods › Statistics · 19 Aug 2024 · 23 likes Time-to-event analysis handles differing follow-up in a way a simple proportion cannot, which is why event rates and Kaplan-Meier estimates can differ. Reading it back,…
Identical chromatograms across two different lots Replied, post #16 · Sourcing › Red flags · 19 Aug 2024 · 0 likes I had written a reply contradicting post #12 and deleted it. Here is what survived. The most useful contribution to this subcategory is a resolved case written up with…
Blind submission and why it changes minds Replied, post #31 · Sourcing › Independent verification · 7 Aug 2024 · 24 likes Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a submission has been blind we note it because blind results are worth…
Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #9 · Evidence › Journal club · 3 Aug 2024 · 0 likes STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially…
Follow-up: Conditions that change the calculus rather than forbidding it Replied, post #8 · Safety › Contraindications · 15 Jul 2024 · 0 likes Before the thread moves on from Conditions — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four…
The mass-error checker and its intended scope Replied, post #58 · Data & Tools › Calculators · 18 Jun 2024 · 21 likes Everything in post #56 holds. The case it does not cover is the one I have. What I want from this mass-error checker thread is the list of things that would need to be…